Aldesleukin Clinical Trials (20 Recruiting)

Showing 1–20 of 20 trials

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

Melanoma

National Cancer Institute (NCI)170 enrolled1 locationNCT02621021

Recruiting

Phase 2

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Endocrine Tumors

National Cancer Institute (NCI)285 enrolled1 locationNCT03412877

Recruiting

Phase 1Phase 2

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Pancreatic CancerGastric CancerColon Cancer+2 more

National Cancer Institute (NCI)110 enrolled1 locationNCT03190941

Recruiting

Phase 1Phase 2

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

Breast CancerPancreatic CancerOvarian Cancer+2 more

National Cancer Institute (NCI)124 enrolled1 locationNCT02830724

Recruiting

Phase 1Phase 2

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Advanced Solid TumorMetastatic CancerCutaneous Melanoma

Aulos Bioscience, Inc.159 enrolled18 locationsNCT05267626

Recruiting

Phase 1Phase 2

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Cervical CancerAnal CancerPenile Cancer+14 more

Christian Hinrichs15 enrolled2 locationsNCT05639972

Recruiting

Phase 2

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Cervical CancerMetastatic CancerAnal Cancer+18 more

Christian Hinrichs20 enrolled3 locationsNCT05686226

Recruiting

Phase 1

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Breast CancerColorectal, CancerOvarian Cancer+4 more

National Cancer Institute (NCI)210 enrolled1 locationNCT06253520

Recruiting

Phase 2

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Metastatic MelanomaMetastatic Renal Cell CarcinomaAdvanced Locoregional Melanoma+1 more

National Cancer Institute (NCI)78 enrolled1 locationNCT05155033

Recruiting

Early Phase 1

Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

Stage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8+1 more

Emory University15 enrolled1 locationNCT05493566

Recruiting

Phase 1

Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis

Gastroesophageal Junction AdenocarcinomaClinical Stage IV Gastric Cancer AJCC v8Metastatic Gastric Carcinoma+2 more

Mayo Clinic15 enrolled1 locationNCT05802056

Recruiting

Phase 1Phase 2

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Sarcoma, SynovialSarcoma,Soft TissueMelanoma Stage IV

Hadassah Medical Organization3 enrolled1 locationNCT05296564

Recruiting

Phase 1Phase 2

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Pancreatic CancerGastric CancerColon Cancer+2 more

National Cancer Institute (NCI)70 enrolled1 locationNCT03745326

Recruiting

Phase 1Phase 2

Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study

Acute Coronary Syndromes

Cambridge University Hospitals NHS Foundation Trust60 enrolled1 locationNCT06427694

Recruiting

Phase 3

High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

Neuroblastoma

St. Anna Kinderkrebsforschung3,300 enrolled126 locationsNCT01704716

Aldesleukin Clinical Trials

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Adding IL-2 to Tebentafusp to Eradicate Cancer Progression

KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

Immunotherapy for the Treatment of Advanced Solid Tumor

Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study

High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)